Mineralys Therapeutics (MLYS) CCO details option and RSU grants
Rhea-AI Filing Summary
Mineralys Therapeutics, Inc. filed an initial ownership report for Chief Commercial Officer Warren Eric. It shows direct holdings of stock options covering 357,000 shares and another 51,300-share option, plus 38,400 shares of common stock. Footnotes describe restricted stock units granted for no cash consideration that vest over four years starting on February 19, 2026. One option grant vests 25% on the first anniversary of April 21, 2025, with the rest vesting in 36 monthly installments, while another vests in 48 equal monthly installments beginning after February 19, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Warren Eric
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 408,300 shares (Direct);
Common Stock — 38,400 shares (Direct)
Footnotes (3)
- F1. Represents restricted stock units (RSUs) that were granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of February 19, 2026, the date of grant.
- F2. The stock option vests as to 25% of the underlying shares on the first anniversary of April 21, 2025, the date of grant, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
- F3. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following February 19, 2026, the date of grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Mineralys Therapeutics (MLYS) Form 3 for Warren Eric report?
The Form 3 reports Chief Commercial Officer Warren Eric’s initial beneficial ownership in Mineralys Therapeutics, including stock options, common shares, and restricted stock units that vest over multi‑year schedules starting in 2025 and 2026.
How many stock options does Mineralys Therapeutics CCO Warren Eric hold?
Warren Eric holds two direct stock option positions: one covering 357,000 shares and another covering 51,300 shares. These options vest over time according to specified schedules beginning on April 21, 2025, and February 19, 2026, respectively.
What common stock ownership is disclosed for Warren Eric at Mineralys Therapeutics (MLYS)?
The filing discloses that Warren Eric directly owns 38,400 shares of Mineralys Therapeutics common stock following the reported transactions. This represents his direct equity stake in the company’s common shares as of the Form 3 reporting date.
How do Warren Eric’s restricted stock units at Mineralys Therapeutics vest?
His restricted stock units were granted for no additional cash consideration and vest in four annual installments. One quarter of the RSUs vest on each one‑year anniversary of February 19, 2026, with each vested unit converting into one share of common stock.
What are the vesting terms of Warren Eric’s April 21, 2025 stock option grant at MLYS?
The April 21, 2025 stock option grant vests 25% of the underlying shares on the first anniversary of that date. The remaining 75% then vest in 36 substantially equal monthly installments, creating a four‑year total vesting period.
How does the February 19, 2026 stock option grant for Mineralys CCO vest?
The stock option tied to February 19, 2026 vests in 48 equal monthly installments. Each month after that grant date, 1/48th of the total shares underlying the option vest, spreading vesting evenly over four years.